



**MAPLE-BROWN ABBOTT**  
INVESTMENT MANAGERS SINCE 1984

# Maple-Brown Abbott Asian Equity Income Fund

## Monthly Commentary – 31 July 2024

This is a marketing communication. Please refer to the prospectus of Maple-Brown Abbott Funds plc as well as the supplement thereto and the Key Investor Information Document in respect of the Maple-Brown Abbott Asian Equity Income Fund (the 'Fund') before making any final investment decisions.

### Market commentary

The Asia ex-Japan region finished the month marginally lower (-0.1% in USD terms) driven by underperformance in North Asian markets of China, South Korea and Taiwan, largely offset by strength in ASEAN markets and India. The US presidential race, Federal Reserve rate outlook and FX volatility also influenced returns within the broader cohort in Asia. In China, officials held the Third Plenum and State Council meeting which prioritised boosting consumption and reducing overcapacity. While a welcome development, policy announcements were largely in-line with market expectations. China's central bank also cut the 1-year and 5-year benchmark lending interest rates by 10bps. Weakness in South Korea and Taiwan markets were due to rotational flows out of AI/semiconductor supply chains on investor concerns around valuations. The Indian government announced the federal budget, which included a focus on agriculture and social spending programs, as well as an increase in capital gains tax. Late in the month, the Bank of Japan hiked the benchmark rate from near zero to 25bps, causing cross-currency volatility.

Regionally, the best performing markets over the month were Thailand (+5.8%), Malaysia (5.2%) and the Philippines (+4.4%) in USD terms, while the worst performing markets were Taiwan (-4.3%), China (-1.3%) and South Korea (-0.5%). On a sector basis, the best performing sectors were Health Care (+9.1%), Utilities (+3.3%) and Consumer Staples (+2.8%), while the worst performing sectors were Information Technology (-2.9%), Materials (-2.4%) and Energy (-1.6%).

### Fund commentary

The Fund delivered 2.4% return in USD terms for the month, outperforming the benchmark return of -0.1%.

A positive contributor to performance was the position in Indian lubricant maker Castrol India. At the end of the month, the company reported robust quarterly results with FY2024Q2 earnings growing at ~3.1% YoY (FY2024H1 earnings grew at ~4.8% YoY). Continuing optimism in Indian mid-caps also helped drive performance.

The portfolio also benefited from JPY strength (~6.5% strengthening against the USD during the month, reversing around half of its weakness YTD) through our four Japanese equity holdings, with Nippon Telegraph & Telephone (NTT) and Meitec Corp. the largest positive contributors. NTT had underperformed YTD but remains a consistent and steady grower in dividends per share (DPS) and shareholder value. Meitec reported solid FY2025Q1 results at the beginning of August with earnings growing at ~24% YoY.

Negative contributors to performance included the Taiwan Semiconductor Manufacturing Co. (TSMC), with investor sentiment partially rotating from the euphoria on AI chip demand YTD and the market also reacting negatively to former US President Trump's rhetoric on Taiwan-related geopolitics. From its peak reached in early Jul-2024, TSMC's share price fell ~13.5%, however the stock is still up ~57.5% YTD (with a significant improvement in long-term outlook happening at the same time).

Two China central state owned enterprises (SOEs), the telecom China Mobile and the oil and gas company CNOOC were also negative contributors for the month, both on little news, pulling back on what appears to be some profit taking (YTD total returns of ~15.7% and ~62.8% respectively to end of Jul-2024).

At the end of the month, the Fund held 34 securities with a total equity exposure of 97.7% and a forecast dividend yield of 4.7%<sup>1</sup>.

<sup>1</sup> The forecast dividend yield shown for the Fund is based on our own forecasts for the 12-month period ending 31 May 2025 of the weighted average dividend yields of the underlying companies held by the Fund as at 31 July 2024. The forecast dividend yield shown for the Fund does not represent actual results. The figure is estimates only and is based on certain assumptions (including estimated earnings and payout ratios for each of the companies) which may be inaccurate or impacted by unknown risks or unanticipated changes in market conditions. The dividend yields shown for the Fund is not guaranteed to occur. Actual outcomes may vary in a materially positive or negative manner.

### Want to find out more?

**Simon Beram**

T +61 2 8226 6231

E [sberam@maple-brownabbott.com](mailto:sberam@maple-brownabbott.com)

W [maple-brownabbott.com](http://maple-brownabbott.com)

Signatory of:



# Maple-Brown Abbott Asian Equity Income Fund

## Monthly Commentary – 31 July 2024

### Performance of Asian Equity Income (%)<sup>2</sup>

Institutional Euro (EUR) <sup>3</sup>	ISIN: IE00B284YS39					
	1 month	3 months	1 year	2 years p.a.	Since 23 May 2022	p.a.
Fund <sup>4</sup>	1.4	4.2	15.4	8.2	8.0	
Benchmark <sup>5</sup>	-1.1	4.5	8.2	3.1	4.2	

### Institutional US Dollar

ISIN: IE000SKBMBF9

Institutional US Dollar	ISIN: IE000SKBMBF9					
	1 month	3 months	1 year	2 years p.a.	Since 13 Jul 2022	p.a.
Fund <sup>4</sup>	2.4	5.4	13.3	11.5	12.0	
Benchmark <sup>5</sup>	-0.1	5.7	6.2	6.2	6.7	

### Performance of Fund (%)<sup>2</sup>

On 23 May 2022, the Fund's name, investment objective and investment policies changed. Prior to the change in May 2022, the Fund was the Maple-Brown Abbott Asia ex-Japan Fund managed by the same investment team.

### Institutional Euro (EUR)<sup>6</sup>

ISIN: IE00B284YS39

Institutional Euro (EUR) <sup>6</sup>	ISIN: IE00B284YS39							
	1 month	3 months	1 year	3 years p.a.	4 years p.a.	5 years p.a.	10 years p.a.	Since Fund launch 19 Oct 2007 p.a.
Fund <sup>4</sup>	1.4	4.2	15.4	4.7	9.6	5.2	6.0	5.4
Benchmark <sup>5</sup>	-1.1	4.5	8.2	-0.3	4.1	4.4	6.0	4.4

### Institutional Euro (USD)<sup>7</sup>

ISIN: IE00B284YS39

Institutional Euro (USD) <sup>7</sup>	ISIN: IE00B284YS39							
	1 month	3 months	1 year	3 years p.a.	4 years p.a.	5 years p.a.	10 years p.a.	Since Fund launch 19 Oct 2007 p.a.
Fund <sup>4</sup>	2.4	5.4	13.3	1.5	7.2	4.6	3.8	3.7
Benchmark <sup>5</sup>	-0.1	5.7	6.2	-3.3	1.8	3.8	3.8	2.7

#### Notes:

<sup>2</sup> Past performance is not a reliable indicator of future performance. Source: Maple-Brown Abbott Ltd, MSCI as at 31 July 2024.

<sup>3</sup> On 23 May 2022, the Fund's name, investment objective and investment policies changed.

<sup>4</sup> The Fund's performance is based on the movement in net asset value per share and is before tax and after all fees and charges. Tax credits are not included in the performance figures. Fund performance is the performance of the share class since strategy change, shown net of fees including re-invested dividends in the base currency of the share class. Performance can go up as well as down, and investors may lose some or all of their capital. Returns and fund costs may increase or decrease as a result of currency and exchange rate fluctuations.

<sup>5</sup> MSCI AC Asia ex-Japan Net Index (relevant currency).

<sup>6</sup> Performance shown is in EUR and relates to the EUR share class which was launched on 19 October 2007. Performance was achieved under circumstances that no longer apply as the Fund's name, investment objective and investment policies changed on 23 May 2022.

<sup>7</sup> Performance shown is in USD and relates to the EUR share class which was launched on 19 October 2007. Performance was achieved under circumstances that no longer apply as the Fund's name, investment objective and investment policies changed on 23 May 2022.

#### Important benchmark information

The Fund is considered to be actively managed as the Fund seeks to outperform the Benchmark. The Fund may hold securities not held by the Benchmark, but the majority of the Fund's securities are likely to be components of the Benchmark with a divergence in security and sector weightings as the Investment Manager uses its discretion to take advantage of investment opportunities. The investment strategy and geographic focus of the Fund will restrict the extent to which the Fund's holdings may deviate from the Benchmark.

#### Disclaimer

This marketing communication is prepared by Maple-Brown Abbott Limited (ABN 73 001 208 564, Australian Financial Services Licence No. 237296) ("Maple-Brown Abbott") on behalf of Maple-Brown Abbott Funds plc (the "UCITS"), an open-ended investment company with variable capital and segregated liability between sub-funds, incorporated in Ireland and authorised by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities. The Maple-Brown Abbott Asian Equity Income Fund (the "Fund") is a sub-fund of the UCITS and Maple-Brown Abbott is the UCITS' discretionary investment manager and distributor. The Manager of the UCITS is Bridge Fund Management Limited ("Manager"). The material in this marketing communication is solely for marketing purposes and is not sufficient to make an investment decision. This marketing communication is not contractually binding, nor required by any applicable laws and must therefore be read in conjunction with the prospectus of the UCITS ("Prospectus") as well as the supplement thereto and the Key Investor Information Document ("KIID") for the Fund, which contains material information not contained herein, including the terms of investment and information regarding investment risks and restrictions, fees and expenses and conflicts of interests. Potential investors should pay particular attention to the risk disclosures in the "Risk Factors" section of the Prospectus and supplement for the Fund. No assurance can be given that the Fund's investment objective will be achieved or that the Fund will generate a positive return. The information in this marketing communication is intended solely for professional investors in the jurisdictions in which the Fund is registered for sale and should not be relied upon for any purpose. The information contained in this marketing communication is not directed at any person in any jurisdiction where the publication or availability of the information is prohibited or restricted by law. Information in this marketing communication is for information purposes only and does not constitute an offer or solicitation by anyone in any jurisdiction. Nothing contained in the marketing communication constitutes financial, legal, tax or other advice of any kind. This marketing communication is not, and must not be treated as, investment advice, investment recommendations, or investment research. Before making any investment decision, you should seek independent investment, legal, tax, accounting or other professional advice as appropriate. The Fund's performance is based on the movement in net asset value per share plus dividends (where applicable) and is before tax and after all fees and charges. Tax credits are not included in the performance figures. Past performance may not be a reliable guide to future performance and prices for shares in the UCITS may fall as well as rise. An investment in the Fund does not represent an investment in, deposit with, or other liability of Maple-Brown Abbott, and is subject to investment risk, including possible delays in repayment and loss of income and principal invested. Neither Maple-Brown Abbott, the UCITS, the Manager nor any of their respective delegates, appointed service providers or other related parties, nor their respective directors or employees make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the income tax or other taxation consequences of, any investment. Any comments about individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold. Any views expressed on individual stocks or other investments are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this marketing communication. Information contained in the marketing communication that has not been derived directly from Maple-Brown Abbott has not been independently verified and may be subject to assumptions and qualifications of the relevant source and this marketing communication does not purport to provide a complete description of all or any such assumptions and qualifications. To the extent permitted by law, neither Maple-Brown Abbott, the UCITS, the Manager nor any of their respective delegates, appointed service providers or other related parties, nor their respective directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of the information contained in this marketing communication, nor do they accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on any part of this marketing communication. Shares in the Fund are issued by the UCITS. Before making a decision whether to acquire, or to continue to hold an investment in the Fund, investors should obtain and consider the current Prospectus, as well as the supplement thereto and the KIID in respect of the Fund. A copy of the English versions of these documents is available at [maple-brownabbott.com](http://maple-brownabbott.com) or by calling +612 8226 6200 and may also be obtained from the Administrator or the Distributor upon request. Where required under national rules, the KIID will also be available in the local language of the relevant EEA Member State. This marketing communication and the information it contains is current as at 31 July 2024 and is subject to change at any time without notice.

A summary of investor rights associated with an investment in the UCITS shall be available in English [here](#). A decision may be taken at any time to terminate the arrangements made for the marketing of the UCITS in any EEA Member State in which it is currently marketed. In such circumstances, Shareholders in the affected EEA Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the UCITS free of any charges or deductions for at least 30 working days from the date of such notification.

Douse Associates (registered in England under No. 10837002 and authorised and regulated by the Financial Conduct Authority) is authorised to distribute this marketing communication to certain UK investors. Hyde Park Investment International Limited (incorporated in Malta, company reference number C 44733) is authorised to distribute this marketing communication to certain UK and EU investors.

#### Swiss investors

Important information for Swiss investors. This is an advertising document.

The Prospectus, the articles of association and the annual and semi-annual reports of the UCITS are available only to Qualified Investors free of charge from the Swiss Representative.

In respect of the shares distributed in Switzerland to Qualified Investors, the place of performance is at the registered office of the Swiss Representative. The place of jurisdiction is at the registered office of the Swiss Representative or at the registered office or place of residence of the investor.

Swiss Representative: FIRST INDEPENDENT FUND SERVICES LTD, Klausstrasse 33, CH-8008 Zurich

Swiss Paying Agent: Helvetische Bank AG, Seefeldstrasse 215, CH-8008 Zurich

MSCI: The MSCI information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. ([www.msci.com](http://www.msci.com)).

### Want to find out more?

Simon Beram

T +61 2 8226 6231

E [sberam@maple-brownabbott.com](mailto:sberam@maple-brownabbott.com)

W [maple-brownabbott.com](http://maple-brownabbott.com)

Signatory of:

